Delivery Order SPE2DB20D3303-SPE2DB25FA1AH
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count bottles, valued at $9,164.04. This competitively awarded, firm fixed-price delivery order, with no set-aside designation, is scheduled for completion by September 24, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the...
- The Defense Logistics Agency awarded a $9,967.87 delivery order to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count bottles, with an ultimate completion date of September 11, 2025. The contract was competitively awarded with no set-aside designation and employs firm fixed price pricing. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count packaging, valued at $2,254.12. This is a firm fixed-price delivery order with no set-aside designation, issued under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive $999.99 billion global pharmaceutical support vehicle running through December...
- The Defense Logistics Agency awarded a delivery order valued at $1,645.28 to AmerisourceBergen Drug Corp for 24,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count bottles. This firm fixed-price delivery order was competitively awarded without a set-aside designation and is scheduled for completion by May 2, 2025. The product will be delivered to the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This...
- The Defense Logistics Agency awarded a delivery order valued at $1,860.27 to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon (pancrelipase) in 100-count bottles. This competitive, firm fixed-price delivery order, with an ultimate completion date of September 11, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The order will be fulfilled from the...
- The Defense Logistics Agency awarded a $35,129.07 delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for 36,000 unit capsules of Creon, a pancreatic enzyme replacement therapy used to treat pancreatic insufficiency. This competitive award, which is not set-aside, represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to...
- The Defense Logistics Agency awarded a delivery order valued at $1,101.10 to AmerisourceBergen Drug Corp on July 24, 2025, for 12,000 unit capsules of Creon (pancrelipase) in 100-count bottles. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, carrying an ultimate completion date of July 25, 2025. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance for this pharmaceutical supply contract. This...
- The Defense Logistics Agency issued a delivery order valued at $14,994.54 to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count packages. This firm fixed-price delivery order, awarded on July 14, 2025, with an ultimate completion date of July 15, 2025, represents a non-competitive award under an existing contract vehicle. The pharmaceutical will be supplied from the vendor's facility in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a $21,057.57 delivery order to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count bottles. This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by September 11, 2025. AmerisourceBergen will perform this delivery order from its corporate headquarters in Conshohocken, Pennsylvania, where the company operates as a major...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of 24,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count bottles, with a contract value of $9,718.75. The order was competitively awarded without set-aside designation and is scheduled for completion by August 20, 2025. Performance will be executed from the contractor's Corporate Office location in Conshohocken, Pennsylvania. This delivery order operates under a firm...
- SPE2DB20D3303Indefinite Delivery Contract
- SPE2DB20D3303-SPE2DB25FA1AHDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count bottles, valued at $1,860.18. The contract is a firm fixed-price delivery order with an ultimate completion date of July 7, 2025, and was awarded on July 3, 2025 without a set-aside designation. Performance will be executed from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 pharmaceutical prime vendor agreement running through December 2026. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen supplies a comprehensive range of medications and medical supplies to support military healthcare systems and other federal agencies. The company's award history demonstrates consistent capability to meet federal procurement requirements through competitive processes, with delivery orders spanning from small-value transactions to substantial orders exceeding $45,000 across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 7/3/25 |